Edurant and Vocabria Now Approved for Pediatric Patients
March 30, 2022Yescarta Granted Approval for Earlier Use in B-Cell Lymphoma
April 1, 2022April 1, 2022 – ViiV Healthcare’s Triumeq PD® (abacavir/dolutegravir/lamivudine) has been approved to treat HIV-1 infection in children who weigh 10kg (22 pounds) to less than 25kg (55 pounds).
- Triumeq PD is a new oral tablet for suspension that contains the same active pharmaceutical ingredients as ViiV Healthcare’s Triumeq® oral tablets.
- Triumeq first received FDA approval in 2014.
- Previously approved only for patients weighing at least 40kg (88 pounds), Triumeq is now indicated for patients who weigh at least 25kg.
- Triumeq and Triumeq PD cannot be interchanged on a milligram per milligram basis due to differences in how the products move through the body.
- Recommended dosing is as follows:
- Triumeq PD: Four to six tablets taken once daily, based on the patient’s weight. The oral tablets for suspension must be fully dispersed in 20mL of drinking water in a cup supplied with the medication. Triumeq PD is not recommended for adults or for children who weigh at least 25kg.
- Triumeq: One tablet taken by mouth once daily. Triumeq is recommended for adults and for children who weigh at least 25kg.
- Triumeq PD has launched at a wholesale acquisition cost (WAC) of $1,001.72 for 90 tablets.